

## ASX Announcement

# Results of 2025 Annual General Meeting

**SYDNEY Australia, 5 November 2025:** In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) Annual General Meeting held today at 9:30am (AEDT) are attached.

All resolutions put to the Annual General Meeting were decided by way of poll.

This announcement has been approved for release by Recce Pharmaceuticals Board.

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

# Disclosure of Proxy Votes

Recce Pharmaceuticals Ltd  
Annual General Meeting  
Wednesday, 05 November 2025



**AUTOMIC**  
Automic  
GPO Box 5193, Sydney, NSW 2001  
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)  
F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)  
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	29,286,979	6,573,418 22.44%	21,009,393 71.74%	242,759	1,704,168 5.82%	14,699,907 19.32%	61,374,994 <sup>(a)</sup> 80.68%	242,759	-
2 Re-election of Dr John Prendergast as Director	P	33,218,403	10,997,793 33.11%	20,506,942 61.73%	20,000	1,713,668 5.16%	59,499,383 74.37%	20,506,942 25.63%	20,000	Carried
3 Re-election of Dr Justin Ward as Director	P	32,886,719	31,089,772 94.54%	83,279 0.25%	351,684	1,713,668 5.21%	79,591,362 99.90%	83,279 0.10%	351,684	Carried
4 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	33,131,644	30,657,670 92.53%	760,306 2.29%	106,759	1,713,668 5.17%	38,632,304 48.34%	41,287,262 51.66%	106,759	Not Carried
5 Ratification of Prior Issue of Placement Shares	P	33,043,127	31,149,360 94.27%	180,099 0.55%	195,276	1,713,668 5.19%	39,285,349 49.21%	40,545,700 50.79%	195,276	Not Carried
6 Ratification of Prior Issue of Warrants	P	32,878,701	30,930,539 94.07%	231,494 0.70%	359,702	1,716,668 5.22%	39,024,528 48.98%	40,642,095 51.02%	359,702	Not Carried

Note: (a) As more than 25% of the votes cast on Resolution 1 were against the adoption of the 2025 Remuneration Report, this constitutes a 'first strike' under section 250U of the Corporations Act 2001 (Cth).

